Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
Ontology highlight
ABSTRACT: Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer's disease (AD) in a manner independent of amyloid β. However, these compounds' clinical prospect for AD is limited due to potential issues, such as poor brain penetration and metabolic instability. Here, we report the development of iP-selective macrocyclic peptide epoxyketones prepared by a ring-closing metathesis reaction between two terminal alkenes attached at the P2 and P3/P4 positions of linear counterparts. We show that a lead macrocyclic compound DB-60 (20) effectively inhibits the catalytic activity of iP in ABCB1-overexpressing cells (IC50: 105 nM) and has metabolic stability superior to its linear counterpart. DB-60 (<
SUBMITTER: Lee MJ
PROVIDER: S-EPMC10913540 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA